Effects of baijiezi powder and its disassembled formula on the ig-e, il-4, ifn-γ and tnf-α in allergic asthmatic rats / 中国药学杂志

OBJECTIVE: To investigate the effects of baijiezi powder and its disassembled formula on the immunoglobulin (Ig)-E, interleukin (IL)-4, interferon (IFN)-γ and tumor necrosis factor (TNF)-α in local skin of applied drugs and lung tissues of rats with allergic asthma. METHODS： Eighty rats were randomly divided into normal control group, model control group, positive control group, baijiezi powder acupoint group, baijiezi powder non-acupoint group, Semen Sinapis Albae acupoint group, Corydalis Rhizoma acupoint group, Radix Kansui acupoint group, asarum acupoint group and Ginger acupoint group, 8 in each group. In addition to the blank control group, the other nine groups were sensitized by ovalbumin (OVA) to establish a model of allergic asthma. The morphological changes of lung tissue were observed by HE staining. The contents of the Ig-E, IL-4, IFN-γ and TNF-α in local skin of application and serum were detected by enzyme-linked immunosorbent assay (ELISA). RESULTS： The infiltration degree of inflammatory cells was obviously reduced and the alveolar structure was basically normal in baijiezi powder acupoint group, which was similar to the normal control group. The levels of the Ig-E, IL-4, IFN-γ and TNF-α in serum can be recalled in each treatment acupoint group. Especially, baijiezi powder acupoint group, Semen Sinapis Albae acupoint group and asarum acupoint group were the best (P < 0.01). The level of Ig-E in the local skin for the drug application of baijiezi powder acupoint group, Semen Sinapis Albae acupoint group and asarum acupoint group was lower than the normal value. CONCLUSION： Baijiezi powder can effectively treat allergic asthma, can signifcantly enhance the IFN-γ and weaken the expression of Ig-E, IL-4 and TNF-α in the local skin of the application and serum. Meanwhile, the correction intensity of each index value in local skin of applied drugs of baijiezi powder was higher than that of serum. Among all the disassembled herbs, Semen Sinapis Albae and asarum have a strong effect on Ig-E, TNF-α and IFN-γ, while Corydalis Rhizoma mainly has an effect on IL-4.

Enfermedades inmunomediadas del sistema nervioso periférico / Peripheral nervous system immunological disorder

Las enfermedades autoinmunes del sistema nervioso periférico son frecuentes en pediatría. Las más importantes son el síndrome de Guillain-Barré, la miastenia gravis juvenil y la dermatomiositis juvenil. Tienen en común ser causadas por acción de anticuerpos específicos que producen la signología clínica, reacción que puede ser gatillada por un cuadro viral o bacteriano, como ocurre principalmente en SGB. La polineuropatía aguda inflamatoria desmielinizante es más frecuente. Existe también la forma axonal motora. Ambas tienen clínica progresiva ascendente. El tratamiento específico es la inmunoglobulina 2 g/ kg. La miastenia gravis juvenil se expresa por signos oculares, generalizados y fatigabilidad fluctuante. Puede comprometer la función respiratoria desencadenando crisis miasténica. Se trata con anticolinesterásicos, corticoides, inmunoglobulinas e inmunosupresores. La timectomía ha mostrado recientemente su efectividad. La dermatomiositis juvenil se expresa por signos cutáneos y musculares. Se diagnostica por elevación de enzimas musculares, biopsia y resonancia musculares y se trata con corticoides, inmunoglobulinas e inmunosupresores. Tanto el síndrome de Guiilain-Barré, como la miastenia gravis y la dermatomiositis juvenil, tienen buen pronóstico.

Autoimmune diseases of the peripheral nervous system are common in pediatrics. Guillain-Barré syndrome, juvenile myasthenia gravis, and juvenile dermatomyositis are the most important. Their common pathogenesis involves the action of specific autoantibodies which are frequently triggered by viral or bacterial infection. Acute inflammatory demyelinating polyneuropathy is the most frequent pathological feature. There is also a motor axonal form. Both have a progressive ascending clinical course. The specific treatment is immunoglobulin 2 g/kg. Juvenile myasthenia gravis is expressed by ocular signs and generalized and fluctuating fatigability. It can involve respiratory functions triggering a myasthenic crisis. It is treated with anticholinesterase agents, corticosteroids, immunoglobulins, and immunosuppressants. Thymectomy has recently shown effectiveness. Juvenile dermatomyositis is expressed by skin and muscle signs. Elevated muscle enzymes, muscle biopsy, and magnetic resonance imaging contribute to the diagnosis. It is treated with corticosteroids, immunoglobulins, and immunosuppressants. All three disorders, Guillain-Barré, juvenile myasthenia gravis, and juvenile dermatomyositis have a good prognosis.

Avances en las inmunoterapias para alergias alimentarias / New insights in immunotherapies for food allergies / Novas perspectivas em imunoterapias para alergias alimentares

Las enfermedades alérgicas son las inmunopatologías que con mayor prevalencia se presentan en el mundo. Pueden o no estar mediadas por anticuerpos IgE, sin embargo estas últimas son las que más intensamente se han estudiado por el riesgo que presentan para la vida del paciente. Si bien el único tratamiento que logra revertir estos mecanismos es la no exposición al alergeno, esto no siempre es posible. Por esta razón, y a partir del mayor conocimiento alcanzado del sistema inmune de mucosas junto al desarrollo de modelos animales de alergia, existe un marcado interés en la especialidad para el desarrollo de inmunoterapias que controlen y reviertan el estado de alergia. A partir de los ensayos pre-clínicos en animales y la aplicación de protocolos terapéuticos en ensayos clínicos, se han desarrollado terapias mucosales que logran inducir mecanismos de tolerancia específicos del alergeno, los cuales son capaces de revertir la sensibilización alérgica. Dado que el principal escollo siguen siendo las reacciones adversas inducidas durante el tratamiento, se requiere profundizar los estudios para desarrollar protocolos terapéuticos más seguros. En este punto la medicina traslacional encuentra un campo próspero para fortalecer las interacciones entre la ciencia básica, la aplicada y la clínica.

Allergic diseases are the most prevalent immunopathologies worldwide. Although different mechanisms -IgE-independent or IgE-dependent- can be involved in the immunopathogenesis, the latter are the most studied reactions since they can be life-threatening. Nowadays, allergen avoidance is the unique effective treatment for allergic patients. However, this is rather difficult to implement. For this reason, and based on the new insights into the mucosal immune system and the development of animal models of allergy, there is an increasing interest in developing novel therapies to control or reverse allergic disorders. Pre-clinical studies and clinical trials have been successful to prove that immunotherapies may accomplish mucosal mechanisms of allergen-specific tolerance, which are able to revoke the allergic sensitization. Since the main obstacle in these therapies still has adverse reactions induced during treatment, further studies are required to explore safe and effective therapeutic protocols. At this point, translational medicine is a flourishing field in the areas of basic science, applied science, and clinical research.

As doenças alérgicas são as imunopatologias mais prevalentes em todo o mundo. Embora possam estar mediadas ou não por anticorpos IgE, estas últimas são as reacções mais intensamente estudadas, devido ao risco que apresentam para a vida do paciente. Ainda que o único tratamento eficaz para reverter este mecanismos seja a não exposição dos pacientes ao alergeno, isto nem sempre é possível. Por este motivo, e com base nas novas perspectivas sobre o sistema imune de mucosas, junto com o desenvolvimento de modelos e para o animais de alergia, existe um interesse crescente na especialidade para o desenvolvimento de imunoterapias que controlem e revertam o estado de alergia. A partir de estudos pré-clínicos em animais e a aplicação de protocolos terapêuticos em ensaios clínico, foram desenvolvidas terapias mucosas que conseguem induzir mecanismos de tolerância específicos do alergeno, que são capazes de reverter a sensibilização alérgica. Devido a que o principal obstáculo nestas terapias continuam sendo as reações adversas induzidas durante o tratamento, é necessário realizar mais estudos para desenvolver protocolos terapêuticos mais seguros. Neste ponto, medicina translacional é um campo próspero para fortalecer as interações entre a ciência básica, a aplicada e a clínica.

Effect of Yupingfeng granule on cytokines of allergic rhinitis induced by OVA in rats / 中国中药杂志

To investigate the effects of Yupingfeng granule (YPF) on immune factors of the rats with allergic rhinitis (AR) induced by ovalbumin(OVA). OVA 0.3 mg, Al(OH)3 30 mg and saline 1 mL were mixed and intraperitoneally injected for the initial immunization, 4% OVA 200 μg (50 μL) was given to the nose on the 15th day for the second immunization to establish the allergic rhinitis model. Sixty male SD rats were randomly divided into allergic rhinitis(AR) model group, Yupingfeng granule three dose (2.7,1.35,0.68 g•kg⁻¹) groups, control drug Biyankang (0.4 g•kg⁻¹) and normal control group. After 14 days, efforts were made to collect blood from abdominal aorta, and take nasopharynx tissues and fasten them into 10% formaldehyde for a pathological examination. The levels of HIS, IgE, IL-4 and TNF-α in serum were examined by radioimmunoassay, and nasal mucosa tissues were examined by HE staining. According to the results, the levels of HIS, IgE, IL-4 and TNF-α in serum of Yupingfeng granule groups were significantly lower than that of AR model group (P<0.05, P<0.01). Nasal mucosa tissues showed slight morphological changes and inflammatory cell infiltration, with unobvious necrosis. Yupingfeng granule can improve the pathological changes of nasal mucosa tissues, and reduce the production and release of immune factors during allergic rhinitis (AR) process in vivo by OVA, which may be the important curative mechanism of allergic rhinitis.

Comparison of Clinical Severity and Laboratory Results between Atopic and Non-atopic Eczema in Children / 소아알레르기및호흡기학회지

PURPOSE: We aim to compare clinical severity of atopic and non-atopic eczema in children and examine the relationship between total-IgE, eosinophil counts, Eosinophil, Eosinophil cationic protein (ECP) and clinical severity of atopic dermatitis (AD). METHODS: A total of 271 children diagnosed with AD at the Pediatric Allergy Respiratory Center in Soonchunhyang University Hospital from October 2005 to March 2008 were enrolled for this study and divided into 2 groups: atopic and non-atopic eczema. Serum concentrations of total- and specific-IgE, eosinophil counts and ECP were measured. Allergy skin tests were also performed and the SCORAD index was used to evaluate clinical severity. Comparisons the SCORAD index and serum total-IgE, eosinophil count and ECP between the 2 groups were made. RESULTS: Of the 271 patients, 162 (59.8%) were included in the atopic eczema group, while 109 (40.2%) were included in the non-atopic group according to the laboratory results. Serum total- IgE, eosinophil counts, ECP, the SCORAD index and the frequency of a family history of eczema were relatively higher in the atopic group. In the atopic group, serum total-IgE, eosinophil counts and ECP each had a statistically significant correlation with the SCORAD index with eosinophil counts showing the highest correlation. However, only eosinophil counts had a statistically significant correlation with the SCORAD index in the non-atopic group. CONCLUSION: Serum total-IgE, eosinophil counts, and ECP can be used as markers for clinical severity in patients with atopic eczema, while eosinophil counts be used as marker for clinical severity in those with non-atopic eczema.

Clinical Significance of Serum ECP and IgE in Children with Asthma / 医学研究杂志

0.05).Conclusions These results suggest that the level of serum ECP can reflect the inflammation in the bronchial tube and the activated state of eosincyte more sensitively than IgE.

A Case of Toxic Epidermal Necrolysis Treated with High Dose Intravenous Immunoglobulin in a 2 Years Old Boy / 소아알레르기및호흡기학회지

Toxic epidermal necrolysis(TEN) is a severe drug induced life-threatening disease and an acute illness. This disease is characterized by rapid onset of widespread necrosis resulting in sloughing of epidermis. The incidence of TEN is very rare, with approximately 0.5 to 1.4 cases per million per year. but TEN has a high mortality rate of 25-40 percent. Therapy for TEN is primarily aimed at supportive care. Treatment with systemic corticosteroid, immunosuppresive agent such as cyclosporine, cyclophosphamide, pentoxifyllin or plasmapheresis have not been shown to improve outcome. Recently, administration of high dose intravenous immunoglobulin(IVIG) has been shown to result in rapid improvement in patients with TEN. There have been several reports of the benefit of IVIG in adult patients with TEN. However we could not find using IVIG in pediatric patient with TEN in Korea. We have experienced improvement in a 2 years old boy with TEN after using high dose IVIG.

Sangrado transvaginal durante el embarazo, como factor de riesgo para isoinmunización al antígeno Rhesus-D / Transvaginal bleeding during pregnancy associated with Rhesus-D isoimmunization

OBJETIVO: Evaluar el sangrado transvaginal en cualquier etapa del embarazo como factor de riesgo para la sensibilización al antígeno eritrocitario Rhesus-D en mujeres previamente no isoinmunizadas (Rh(-)NI), como una alternativa para la aplicación rutinaria de gama-globulina anti-D a la semana 28 de gestación. MATERIAL Y MÉTODOS: Estudio de casos y controles consecutivos, efectuado en el Instituto Nacional de Perinatología de la Ciudad de México, en el periodo de 1995 a 2001.Casos (n=24), pacientes Rh(-)NI que mostraron seroconversión positiva de anticuerpos contra el componente D del antígeno Rh durante el embarazo o en el puerperio inmediato. Controles (n=24), mujeres Rh(-)NI, captadas consecutivamente y que no presentaron seroconversión positiva de anticuerpos Anti-D. En todos los casos los recién nacidos fueron Rh positivos. Ninguna de las pacientes recibió inmunoprofilaxis Anti-D a la semana 28 de gestación. Se evaluaron periodos de sangrado transvaginal en cualquier etapa del embarazo y antes del inicio del trabajo de parto. Se estimaron razones de probabilidad e intervalos de confianza de 95 por ciento. RESULTADOS: La presencia de sangrado transvaginal se observó en 18/24 (75 por ciento) de los casos y en 5/24 de los controles (20 por ciento). La actividad uterina pretérmino y la amenaza de aborto fueron las causas más frecuentes identificadas como causa de este sangrado. La presencia de uno solo de estos eventos durante cualquier etapa del embarazo aumentó 11.4 veces (IC 95 por ciento 2.9-44.0) el riesgo de sensibilización al antígeno eritrocitario Rh-D, y si el sangrado se presentó después de la semana 20 el riesgo se incrementó 5.0 veces (IC 95 por ciento 1.3-19.1). La presencia de sangrado antes de la semana 20 no se asoció con un incremento significativo en el riesgo de sensibilización (OR=7.6, IC 95 por ciento 0.8-69.5). CONCLUSIONES: En presencia de cualquier sangrado transvaginal durante el embarazo en una paciente Rh-NI...

OBJECTIVE: The aim of the present study was to evaluate transvaginal bleeding (TVB) as a risk factor for Rhesus isoimmunization during pregnancy, in order to optimize the application of Anti-D gammaglobulin in non-immunized pregnant women, as an alternative to the routine application of Anti-D at 28 weeks of gestation. MATERIAL AND METHODS: This case-control study was conducted from 1995 to 2001 at Mexico's National Perinatology Institute. Cases (n=24) were non-immunized pregnant women who showed positive anti-D antibody seroconversion during pregnancy or during the early puerperium. Controls (n=24) were non-immunized pregnant women who enrolled after each case, with similar clinical characteristics but who had no anti-D antibody seroconversion during pregnancy. In all cases the newborns were Rh-positive. None of the patients received immunoprofilaxis at 28 weeks of gestation. The presence of TVB was recorded at any stage of pregnancy and before labor. Odds ratios with 95 percent confidence intervals were used to assess associations. RESULTS: TVB was observed in 18/24 (75 percent) cases and in 5/24 (20 percent) controls. Preterm uterine contractions and threatened miscarriage were the most frequent causes of TVB. The presence of one TVB event during pregnancy increased 11.4 times (95 percent CI 2.9-44.0) the likelihood of Rhesus isoimmunization. TVB after 20 weeks of gestation increased the likelihood 5.0 times (95 percentCI 1.3-19.1). TVB before 20 weeks of gestation was not significantly associated with Rh isoimmunization (OR=7.6, 95 percentCI 0.8-69.5). CONCLUSIONS: Prophylaxis with anti-D gammaglobulin should be given to all non-immunized Rhesus-negative pregnant woman with TVB at any stage of pregnancy.